BioSpace News Archive

TG Therapeutics, Inc., announced data presentations at the 25th European Hematology Association annual congress including data from a Phase 1 study evaluating TG-1701

Imago BioSciences announced the presentation of data at the 2020 Virtual European Hematology Association meeting relating to the clinical trial of bomedemstat for the treatment of advanced myelofibrosis.

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Colchicine Tablets USP, a therapeutic equivalent generic version of Colcrys® (colchicine) Tablets, 0.6 mg, approved by the U.S. Food and Drug Administration (USFDA).

Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced that Nassim Usman, Ph.D., president and chief executive officer of Catalyst Biosciences, will present a corporate overview at the Raymond James Human Health Innovation Conference at 3:00 pm ET on Thursday, June 18, 2020. To access a live webcast of the presentation, please visit https://kvgo.com/raymondjames/Catalyst-Biosciences-june-2020 An archived webcast of the p

PRA Health Sciences, Inc. (NASDAQ: PRAH) announced today the enhancement of its commercial Health Harmony COVID-19 Monitoring Program with the integration of the Microsoft Healthcare Bot service.

Tolero Pharmaceuticals, Inc., a clinical-stage company focused on developing novel therapeutics for hematological and oncological diseases, today presented data from the completed Phase 1 Zella 101 study evaluating the investigational agent alvocidib, a potent CDK9 inhibitor, in adult patients with newly diagnosed acute myeloid

Amsterdam Facility will Bring Kite’s Potentially Life-Saving Individualized Treatment Closer to People with Advanced Blood Cancers in the European Region --

Vaxcyte, Inc. announced the pricing of its upsized initial public offering of 15,625,000 shares of common stock at a public offering price of $16.00 per share.

The agreement furthers Anthos Therapeutics mission to develop Abelacimab for patients at risk of thrombotic events, which are currently underserved by conventional anti-coagulant therapies.

VALBIOTIS announces that the main results of its international Phase II clinical study demonstrating the metabolic benefits of TOTUM-63 in prediabetic patients are being presented at the 80th Scientific Sessions of the American Diabetes Association.